Empatica has launched EpiMonitor, an epilepsy monitoring system for adults and children aged six and above.
Approved by the US Food and Drug Administration (FDA), EpiMonitor is an advanced wearable technology designed to detect generalised tonic-clonic seizures with high accuracy.
Go deeper with GlobalData
A successor to Empatica’s Embrace2 device, EpiMonitor has features such as improved seizure alert capabilities, a battery life of up to one week, and advanced health insights.
It operates using Empatica’s EmbracePlus medical watch, which has undergone numerous clinical trials.
The companion smartphone app and algorithms work in tandem to monitor health data, detect potential seizures, and alert caregivers promptly.
Empatica said the device has a 98% accuracy rate in seizure detection, with a low false alarm rate, and can send automatic alerts to caregivers via call and SMS, including the user’s location.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEpiMonitor also offers a user-friendly mobile app, which includes a seizure diary, and the ability to track sleep and activity through Empatica’s proprietary algorithms.
Users can also generate reports on seizures, sleep, and activity, which can be shared with physicians.
Furthermore, the system is compatible with both iOS and Android smartphones.
Empatica chief scientist and co-founder Dr Rosalind Picard said: “Empatica has always provided the only smartwatch seizure monitors validated by the FDA.
“Our new solution, Epimonitor, takes this to a new level: giving patients up to 7 days of battery life, and new features that give them greater control over seizure alerts.
“Also, at the touch of a button, patients can now see comprehensive health insights – including seizures, sleep, and activity reports – in a form easy to give their clinician.”
Empatica is planning to undertake a pioneering study to develop a seizure forecasting algorithm, leveraging the largest real-world data set in patients with epilepsy.
Last year, Empatica obtained FDA 510(k) clearance for two new digital biomarkers, namely pulse and respiratory rate, for its health monitoring platform.
